CBT
MRNA icon

Central Bank & Trust’s Moderna MRNA Stock Holding History

Central Bank & Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-148
Closed -$14.7K – 354
2023
Q4 		$14.7K Hold
148
– – ﹤0.01% 292
2023
Q3 		$15.3K Hold
148
– – ﹤0.01% 268
2023
Q2 		$18K Sell
148
-10
-6% -$1.33K ﹤0.01% 258
2023
Q1 		$24.3K Buy
158
+10
+7% +$1.65K ﹤0.01% 247
2022
Q4 		$26.6K Hold
148
– – 0.01% 246
2022
Q3 		$18K Hold
148
– – ﹤0.01% 255
2022
Q2 		$21K Hold
148
– – ﹤0.01% 257
2022
Q1 		$25K Buy
148
+43
+41% +$7.24K ﹤0.01% 253
2021
Q4 		$27K Hold
105
– – ﹤0.01% 256
2021
Q3 		$40K Hold
105
– – 0.01% 236
2021
Q2 		$25K Sell
105
-300
-74% -$53.6K ﹤0.01% 247
2021
Q1 		$53K Sell
405
-225
-36% -$32.6K 0.01% 207
2020
Q4 		$66K Buy
630
+235
+59% +$23.8K 0.01% 193
2020
Q3 		$28K Sell
395
-27
-6% -$1.88K 0.01% 217
2020
Q2 		$27K Buy
+422
New +$23.1K 0.01% 199

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Central Bank & Trust's MRNA Position: Q1 2024 in Review

Central Bank & Trust sold out of Moderna (MRNA) in Q1 2024, closing a stake of 148 shares — an estimated $14.7K sold.

Central Bank & Trust first reported a position in MRNA in Q2 2020 and held it in 15 quarters. The position peaked at $66K in Q4 2020. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Central Bank & Trust reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Central Bank & Trust sold 148 Moderna shares in Q1 2024, an estimated $14.7K.
  • Central Bank & Trust first reported a position in Moderna in Q2 2020 and held it in 15 quarters.
  • Central Bank & Trust's Moderna position peaked at $66K in Q4 2020.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Central Bank & Trust's 13F filing for Q1 2024, filed 11 Apr 2024.